• / Free eNewsletters & Magazine
  • / My Account
Home>Search Results

Related Content

  1. Videos
  2. Articles
  1. Lorillard Bonds Attractive Ahead of FDA Ruling

    Worries about the FDA's ruling on the relative safety of menthol cigarettes have left Lorillard's bonds looking attractively priced according to Morningstar's Dave Sekera.

  2. Generic Biologics Face Uphill Battle

    Morningstar generic-pharmaceuticals analyst Brian Laegeler discusses the outlook for generic biologics in the U.S. given a strong branded-drug lobby and complex manufacturing processes.

  3. Will 'Knockout' Mice Make a Knockout Stock?

    After a strong runup from our recommendation, is it time to take money off the table in Lexicon Pharmaceuticals?

  4. Going Global to Ease Drug Trial Process

    Contract research organization Parexel is exploiting its global footprint to rapidly enroll patients in drug studies.

  1. Isis Pharmaceuticals ISIS Q2 2012 Earnings Call Transcript

    Good day, ladies and gentlemen, and welcome to Isis Pharmaceuticals' Second Quarter Financial Results Conference Call. Leading the call today from Isis is Dr. Stanley Crook, Isis's Chairman and Chief Executive Officer. Dr. Crook, please begin.

  2. Will Regulatory Issues Hold Monster Back in 2013?

     

  3. Jazz Pharmaceuticals, Inc. JAZZ Q4 2011 Earnings Call Transcript

    Good day ladies and gentlemen and welcome to Jazz Pharmaceuticals Full Year and Fourth Quarter 2011 Financial Results Conference Call. Following an introduction from the Company, we will open the call to questions.

  4. Salix Pharmaceuticals, Ltd. SLXP Q4 2010 Earnings Call Transcript

    Good day everyone and welcome to the Salix Pharmaceuticals Fourth Quarter 2010 Earnings Release Conference Call. Today's conference is being recorded.

1
ShareEmail
Print
Text Size
Comment
blog comments powered by Disqus
Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.